| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 22 Jan 2026 | 33 | 55% | 38% | 7% | 45% |
| 01 Jan 2025 - 30 Jun 2025 | 28 Jul 2025 | 47 | 35% | 41% | 24% | 65% |
| 01 Jul 2024 - 31 Dec 2024 | 29 Jan 2025 | 29 | 56% | 42% | 2% | 44% |
| 01 Jan 2024 - 30 Jun 2024 | 26 Jul 2024 | 31 | 55% | 43% | 2% | 36% |
| 01 Jul 2023 - 31 Dec 2023 | 30 Jan 2024 | 31 | 52% | 47% | 1% | 48% |
| 01 Jan 2023 - 30 Jun 2023 | 18 Jul 2023 | 32 | 47% | 53% | 1% | 54% |
| 01 Jul 2022 - 31 Dec 2022 | 17 Jan 2023 | 58 | 48% | 47% | 5% | 55% |
| 01 Jan 2022 - 30 Jun 2022 | 28 Jul 2022 | 32 | 48% | 51% | 1% | 55% |
| 01 Jul 2021 - 31 Dec 2021 | 21 Jan 2022 | 29 | 58% | 41% | 2% | 46% |
| 01 Jan 2021 - 30 Jun 2021 | 30 Jul 2021 | 72 | 24% | 21% | 55% | 67% |
| 01 Jul 2020 - 31 Dec 2020 | 26 Jan 2021 | 32 | 48% | 51% | 1% | 51% |
| 01 Jan 2020 - 30 Jun 2020 | 27 Jul 2020 | 37 | 32% | 66% | 3% | 62% |
| 01 Jul 2019 - 31 Dec 2019 | 27 Jan 2020 | 26 | 67% | 33% | 0% | 30% |
| 01 Jan 2019 - 30 Jun 2019 | 22 Jul 2019 | 21 | 90% | 8% | 2% | 10% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 23 | 91% | 6% | 3% | 9% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 24 | 83% | 13% | 4% | 17% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Payment made on undisputed amounts 30-45 Days after receipt of the invoice. Once an invoice is approved it is sent for payment in the next available weekly payment ru
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
Gilead reserves the right to withhold payment of any invoice or part of an invoice to the extent that the services/goods provided are not in accordance with the agreement entered into. We also reserve the right to set off any liability of Supplier to Gilead against any liability of Gilead to Supplier.
Maximum contractual payment period agreed
45
Each engagement with a supplier will be managed by a Gilead business owner. Should a dispute arise in relation to payment for such engagement, it will be discussed by the supplier and the relevant Gilead business owner as soon as possible and escalated internally with a view to reaching resolution.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
GILEAD SCIENCES LTD is a biopharmaceutical company that focuses on developing innovative treatments for life-threatening diseases. The company was founded in 1987 and is headquartered in Cambridge, United Kingdom.
The company's sustainability program is centered around reducing its environmental impact and promoting social responsibility. GILEAD SCIENCES LTD has set ambitious goals to reduce its carbon footprint, water usage, and waste generation. The company also prioritizes diversity and inclusion in its workforce and partners with local communities to support healthcare initiatives.
GILEAD SCIENCES LTD offers a range of products and services in the areas of HIV, hepatitis, cancer, and respiratory diseases. Its flagship product, Truvada, is a leading treatment for HIV and has been instrumental in reducing the spread of the virus. The company also offers treatments for hepatitis B and C, including Vemlidy and Sovaldi. In addition, GILEAD SCIENCES LTD has a strong pipeline of potential treatments for various diseases.
The key people at GILEAD SCIENCES LTD include Chairman and CEO, Daniel O'Day, who has been with the company since 2019. Other key executives include Chief Scientific Officer, John McHutchison, and Chief Financial Officer, Robin Washington.
The company's website address is www.gilead.com, where customers can find information on its products and services, clinical trials, and company news. The registered office address of GILEAD SCIENCES LTD is 280 High Holborn, London, WC1V 7EE, United Kingdom.
In conclusion, GILEAD SCIENCES LTD is a leading biopharmaceutical company with a strong commitment to sustainability and developing life-saving treatments. Its products and services, along with its dedicated team of executives, have made it a trusted name in the healthcare industry.
Proud of your payment record? Show your live score on your own site:
<iframe src="https://paymentcheck.co.uk/badge/02543818" width="240" height="72" style="border:0" title="PaymentCheck Score" loading="lazy"></iframe>